 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Daewoong Pharmaceutical announced on the 11th that it has signed a joint development, technology export and product supply contract with global pharmaceutical company Zydus Worldwide DMCC on the right to develop and commercialize the Depot (Depot) injection of its anti-cancer drug candidate "DWJ108U."
According to the company, through this contract, Daewoong Pharm is responsible for non-clinical, manufacturing, and supply to launch DWJ108U as the first generic in the US market. Zydus conducts clinical development and commercialization. The contract amount is about 120 billion won, and the contract period is up to seven years after the first sale. In addition to the contract amount of 120 billion won, a significant percentage of local revenue is to be distributed every year.
The two companies aim to develop DWJ108U as the first generic drug in the United States of 'Loupron Depot'.
The Zydus Group, which includes Zydus, is a global pharmaceutical group headquartered in Ahmedabad, India, with 36 production plants worldwide. Of these, 14 facilities have been certified by the US Excellent Medicine Manufacturing and Quality Control Standards (cGMP). Zeiders ranks fifth in the U.S. generic medicine industry in 2022, with annual sales of about 1.2 trillion won and global sales of about 2.7 trillion won.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
